3 results
Approved WMOCompleted
Primary objective of this study is to assess the safety and tolerability, feasibility and biological activity (immunogenicity) of the actively personalized vaccination (APVAC) concept in newly diagnosed glioblastoma (GB) patients.Secondary study…
Approved WMOCompleted
The proportion of patients in GC-free remission after 20 weeks.
Approved WMORecruiting
The aim of this study is to investigate non-inferiority of rituximab SC 336 mg to rituximab IV 200 mg.